Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study

Lee, Soo Hyun; Yoon, Sang Hyun; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang Hyub; Choi, Hye Jin

doi:10.1007/s10637-011-9634-4

Cited by 11 publications

(7 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously said, there are no significant data about comparison between sorafenib and chemotherapeutic drugs, being the lack of phase III randomized trials a reason. As a matter of fact, this comparison was evaluated only retrospectively[ 71 ] with no significant difference in overall survival (23 wk vs 43.6 wk, P = 0.105) and progression free survival (11.1 wk vs 12.4 wk, P = 0.496). More efforts were done to assess a possible synergistic effect of sorafenib plus chemotherapeutic agents.…”

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Chemotherapy for hepatocellular carcinoma: The present and the future

Grazie¹,

Biagini²,

Tarocchi³

et al. 2017

WJH

156

137

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. Its relationship to chronic liver diseases, in particular cirrhosis, develops on a background of viral hepatitis, excessive alcohol intake or metabolic steatohepatitis, leads to a high incidence and prevalence of this neoplasia worldwide. Despite the spread of HCC, its treatment it’s still a hard challenge, due to high rate of late diagnosis and to lack of therapeutic options for advanced disease. In fact radical surgery and liver transplantation, the most radical therapeutic approaches, are indicated only in case of early diagnosis. Even local therapies, such as transarterial chemoembolization, find limited indications, leading to an important problem regarding treatment of advanced disease. In this situation, until terminal HCC occurs, systemic therapy is the only possible approach, with sorafenib as the only standard treatment available. Anyway, the efficacy of this drug is limited and many efforts are necessary to understand who could benefit more with this treatment. Therefore, other molecules for a targeted therapy were evaluated, but only regorafenib showed promising results. Beside molecular target therapy, also cytotoxic drugs, in particular oxaliplatin- and gemcitabine-based regimens, and immune-checkpoint inhibitors were tested with interesting results. The future of the treatment of this neoplasia is linked to our ability to understand its mechanisms of resistance and to find novel therapeutic targets, with the objective to purpose individualized approaches to patients affected by advanced HCC.

show abstract

Section: Cytotoxic Chemotherapymentioning

confidence: 99%

Chemotherapy for hepatocellular carcinoma: The present and the future

Grazie¹,

Biagini²,

Tarocchi³

et al. 2017

WJH

156

137

View full text Add to dashboard Cite

show abstract

“…The models would be critical in supporting clinical decision-making in following up the patients [13]. The concern that arises in the treatment of HCC is that curative treatments are not feasible as patients present with intermediate or advances stages of the disease [14]. However, in all cases, the appropriate management need to take into account the tumor stage, patient's fitness levels and the degree of underlying chronic liver disease because of their independent prognostic significance and potential of negatively affecting liver parenchyma in a manner that make adequate hepatic deserve to be a requisite or safe systemic and loco regional therapy [10].…”

Section: Treatmentmentioning

confidence: 99%

Hepatocellular Carcinoma: Review of Current Treatment with a Focus on Transarterial Chemoembolization and Radiofrequency Ablation

Chhaniwal¹,

Li²,

Wang³

et al. 2015

OJRad

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most deadly tumors and its incidence has been rising worldwide. In its various stages, several modalities of treatment and therapies have been developed. Appropriate HCC treatment needs to consider the tumor stage, underlying liver disease and patient's performance levels. Liver transplantation is an effective treatment but unreliable due to scarcity of donors, whereas surgical resection possesses the potential to achieve long-term survival. However, most tumors are not resectable due to their size, location, number and the function of the liver being compromised. Thus, resection is the first choice treatment for resectable tumors only. This prompts the rise of transarterial chemoembolization (TACE) for unresectable HCC. Progressively, radiofrequency ablation (RFA) arose though it exhibits high postoperative recurrence and cancer mortality. Notably, identifying the best-suited treatment is critical in enabling maximum long-term survival. Though HCC is an identified chemoresistant tumor, chemotherapies have been developed for advanced HCC. Among them, sorafenib, blocks tumor cell proliferation thus improving patient survival, even though costly. In comparison to RFA, TACE has been identified to have more complications and symptoms. However, it demonstrates improved survival benefits and quality of patient care more than symptomatic supportive care. Furthermore, for unresectable HCC, TACE can replace the costly and modestly effective sorafenib treatment; whereas RFA is potentially curative in treating HCC and an alternative to liver transplantation or surgical resection in the early HCC stages. It treats primary and secondary liver tumor in the very early N. Chhaniwal et al. 51 stage HCC. Its reliance on image guidance is minimally invasive and enhances its efficacy and safety, especially where surgery will not have been possible. However, skin burns, hemorrhage, hepatic abscess and pleural effusion are complications that accompany RFA prompting the need for additional treatment.

show abstract

“…However, only a minority of patients are candidates for these procedures, because of tumor extent or underlying liver dysfunction. Sorafenib is the only reference standard systemic treatment for advanced HCC with a modest survival benefit [ 3 , 4 ]. New alternative treatment strategies are needed for HCC.…”

Section: Introductionmentioning

confidence: 99%

A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer

Tagaram

Desai

et al. 2016

Pharmaceuticals

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the third most deadly cancer in the world. New treatment strategies are desperately needed due to limited standard therapies. Activation of the Erk, Akt, and STAT3pathways is implicated in the prognosis of HCC. The Se,Se′-1,4-phenylenebis(1,2-ethanediyl) bisisoselenourea (PBISe), is a selenium-containing MAPK and PI3 kinase inhibitor, effectively inhibit tumorigenesis in a variety of experimental models. The aim of our study is to demonstrate the potential role of PBISe in the treatment of HCC. The anti-proliferative and pro-apoptotic ability of PBISe is studied in vitro in four human HCC cell lines and in vivo in a spontaneous murine HCC model. Inhibition of cancer growth was performed by cell viability assay and apoptosis by caspase 3/7, PARP cleavage, annexin-V, and TUNEL assays. Role of PBISe on PI3 kinase, MAPK and STAT3 signaling is determined by Western blotting. In vivo effects of PBISe on tumor sizes were monitored using MRI in a spontaneous murine HCC. Liver tissues from the PBISe-treated mice are analyzed for angiogenesis, proliferation, and signaling pathway markers. Overall, PBISe activated caspase-3/7 and increased DNA fragmentation, which is positively correlated with the increased PARP cleavage. PBISe promoted apoptosis by inhibiting PI3K, MAPK, and STAT3 signaling with significant reduction in the tumor sizes (p < 0.007). PBISe-treated tumors reduced survival marker PCNA, and angiogenesis markers Vegf-A, Vegf-R3 and CD34. These results demonstrate the chemotherapeutic effects of PBISe, by inhibiting tumor growth and facilitating tumor apoptosis for HCC treatment.

show abstract

Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study

Cited by 11 publications

References 28 publications

Chemotherapy for hepatocellular carcinoma: The present and the future

Chemotherapy for hepatocellular carcinoma: The present and the future

Hepatocellular Carcinoma: Review of Current Treatment with a Focus on Transarterial Chemoembolization and Radiofrequency Ablation

A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer

Contact Info

Product

Resources

About